Nuestro sitio web utiliza cookies para mejorar y personalizar su experiencia y para mostrar anuncios (si los hay). Nuestro sitio web también puede incluir cookies de terceros como Google Adsense, Google Analytics, Youtube. Al usar el sitio web, usted consiente el uso de cookies. Hemos actualizado nuestra Política de Privacidad. Por favor, haga clic en el botón para consultar nuestra Política de Privacidad.

Why targeting NLRP3 remains crucial in drug development for inflammatory diseases

Why targeting NLRP3 remains crucial in drug development for inflammatory diseases
Contents
  1. What inflammasomes and PANoptosomes are
  2. How the main sensors switch on
  3. Where drug development stands
  4. What remains unknown
  5. References

A review by four immunologists at St. Jude Children’s Research Hospital, published in Cell Research on Sept. 4, 2026, explains how innate immune sensors assemble into inflammasomes and PANoptosomes, the protein complexes that set off inflammation and inflammatory cell death. Its main conclusions are that cryo-electron microscopy has shown how several sensors switch from a resting to an active form, that most drug candidates so far target a single sensor, NLRP3, and that no complete structure of an assembled inflammasome or PANoptosome has yet been solved.

The researchers Saurabh Upadhyay, Raghavendra Nagampalli, Sara Resende along with Thirumala-Devi Kanneganti review existing studies instead of detailing a novel trial, and the publication is made available with open access.

What inflammasomes and PANoptosomes are

Inflammasomes are complexes that activate the enzyme caspase-1. Caspase-1 matures two inflammatory signaling molecules, IL-1β and IL-18, and cuts the protein gasdermin D, which opens pores in the cell membrane.

PANoptosomes drive PANoptosis, an inflammatory form of cell death that combines features of pyroptosis, apoptosis and necroptosis. Inflammasomes can be part of them, and they also release other signals such as TNF and interferons. The sensors the review places in PANoptosomes include ZBP1, AIM2, RIPK1, NLRP3, NLRP1, NLRC5 and NLRP12.

How the main sensors switch on

NLRP3 rests in a cage-like cluster until the protein NEK7 binds to it. It then reorganizes into a disk-shaped complex that grows filaments to recruit the adapter protein ASC. AIM2 switches on when it binds double-stranded DNA, which releases its self-inhibition.

SensorWhat activates or restrains itConditions the review links to it
NLRP3Triggered following NEK7 bindingCryopyrin-associated periodic syndromes (CAPS); Alzheimer’s and Parkinson’s disease
NLRP1Suppressed by DPP9 until a detached fragment builds filamentsSkin and autoimmune conditions; traumatic brain injury
NAIP/NLRC4NAIP recognizes bacterial molecules like flagellin to oligomerize NLRC4Enterocolitis caused by gain-of-function mutations
PyrinIts triggering relies on phosphorylation controlled by Rho GTPases alongside 14-3-3 proteinsFamilial Mediterranean fever (FMF)

The evaluation additionally links such pathways to infections—which they assist in combating and pathogens attempt to thwart—as well as to obesity, diabetes, gout, along with cardiovascular and renal disorders. Regarding malignancies, their function varies according to the circumstances, with research documenting both tumorigenic and tumor-inhibiting impacts.

Where drug development stands

Most candidates target NLRP3. MCC950, the best-known inhibitor, holds the sensor in its inactive shape, but its clinical development has been limited by off-target toxicity and by its failure to block some CAPS-causing variants. Other NLRP3 agents include CY-09, dapansutrile (OLT1177) and molecules that degrade NEK7, and the review notes that some have reached clinical evaluation.

Further down the pathway, the review covers blocking caspase-1 and gasdermin D. For FMF, colchicine remains the most widely used treatment, although it does not act specifically on Pyrin. The authors suggest that targeting individual sensors, rather than shared parts such as ASC or caspase-1, could make treatments more precise, and they name IL-1β, IL-18, C-reactive protein and ferritin as possible markers of disease activity.

What remains unknown

There is still no atomic-resolution structure of a fully assembled inflammasome or PANoptosome, and many proposed PANoptosome architectures are inferred from genetic, biochemical and imaging data. NLRC5 and NLRP12 are known only at the level of individual domains, and Pyrin’s full architecture is unresolved. Most structural studies also used a single trigger, which may not reflect the body, where several signals arrive at once.

References

By Olivia Rodriguez

Related posts